Significant efficacy of single low dose primaquine compared to stand alone artemisinin combination therapy in reducing gametocyte carriage in Cambodian patients with uncomplicated multidrug resistant Plasmodium falciparum malaria

Archive ouverte

Vantaux, Amélie | Kim, Saorin | Piv, Eakpor | Chy, Sophy | Berne, Laura | Khim, Nimol | Lek, Dysoley | Siv, Sovannaroth | Mukaka, Mavuto | Taylor, Walter | Ménard, Didier

Edité par CCSD ; American Society for Microbiology -

International audience. Since 2012, single low dose of primaquine (SLDPQ, 0.25mg/kg) has been recommended with artemisinin-based combination therapies, as first-line treatment of acute uncomplicated Plasmodium falciparum malaria, to interrupt its transmission, especially in low transmission settings of multidrug, including artemisinin, resistance. Policy makers in Cambodia have been reluctant to implement this recommendation due to primaquine safety concerns and lack of data on its efficacy.In this randomized controlled trial, 109 Cambodians with acute uncomplicated P. falciparum malaria received dihydroartemisinin-piperaquine (DP) alone or combined with SLDPQ on the first treatment day. Transmission-blocking efficacy of SLDPQ was evaluated on Days 0, 1, 2, 3, 7, 14, 21, 28 and recrudescence by reverse transcriptase polymerase chain reaction (RT-PCR) (gametocyte prevalence) and membrane-feeding assays with Anopheles minimus mosquitoes (gametocyte infectivity). Without the influence of recrudescent infections, DP+SLDPQ reduced gametocyte carriage 3 fold compared to DP. Of 48 patients tested on Day 0, only three patients were infectious to mosquitoes (∼6%). Post-treatment, three patients were infectious: on D14 (3.5%, 1/29), and on the first and seventh day of recrudescence (8.3%, 1/12 for each); this overall low infectivity precluded our ability to assess its transmission blocking efficacy.Our study confirms effective gametocyte clearance of SLDPQ when combined with DP in multidrug resistant P. falciparum and the negative impact of recrudescent infections due to poor DP efficacy. Artesunate-mefloquine (ASMQ) has replaced DP and ASMQ-SLDPQ has been deployed to treat all P. falciparum symptomatic patients to further support the elimination of multidrug resistant P. falciparum in Cambodia.

Suggestions

Du même auteur

Contribution to Malaria Transmission of Symptomatic and Asymptomatic Parasite Carriers in Cambodia

Archive ouverte | Vantaux, Amélie | CCSD

International audience. Background:Eliminating falciparum malaria in Cambodia is a top priority, requiring the implementation of novel tools and strategies to interrupt its transmission. To date, few data are availa...

Anopheles ecology, genetics and malaria transmission in northern Cambodia

Archive ouverte | Vantaux, Amélie | CCSD

Erratum in Publisher Correction: Anopheles ecology, genetics and malaria transmission in northern Cambodia. Vantaux A, Riehle MM, Piv E, Farley EJ, Chy S, Kim S, Corbett AG, Fehrman RL, Pepey A, Eiglmeier K, Lek D, Siv S, Mu...

Field Trial Evaluation of the Performances of Point-of-Care Tests for Screening G6PD Deficiency in Cambodia

Archive ouverte | Roca-Feltrer, Arantxa | CCSD

International audience. BACKGROUND:User-friendly, accurate, point-of-care rapid tests to detect glucose-6-phosphate dehydrogenase deficiency (G6PDd) are urgently needed at peripheral level to safely recommend primaq...

Chargement des enrichissements...